[Effect of pioglitazone, one of TZDs, on IGT-patients].
Kobayashi
Masashi
M
First Department of Medicine, Toyama Medical and Pharmaceutical University.
D052242:Adiponectin; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control*; D015870:Gene Expression / Q000187:drug effects; D018149:Glucose Intolerance / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics; D020738:Leptin / Q000235:genetics; D050356:Lipid Metabolism; D047495:PPAR gamma / Q000819:agonists; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D052242:Adiponectin; D007004:Hypoglycemic Agents; D007328:Insulin; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin; D047495:PPAR gamma; D045162:Thiazolidinediones; D014409:Tumor Necrosis Factor-alpha; D000077205:Pioglitazone